Skip to main content

Market Overview

Daiichi Sankyo - AstraZeneca Start Dosing In Head-To-Head Stomach Cancer Trial With Enhertu

Share:
Daiichi Sankyo - AstraZeneca Start Dosing In Head-To-Head Stomach Cancer Trial With Enhertu
  • Daiichi Sankyo Co Ltd (OTC: DSKYF) and AstraZeneca plc (NASDAQ: AZNhave dosed the first patient in DESTINY-Gastric04, Phase 3 trial of Enhertu (trastuzumab deruxtecan) for gastric or gastroesophageal junction (GEJ) adenocarcinoma.
  • The trial will evaluate the safety and efficacy of Enhertu compared to ramucirumab/paclitaxel combination therapy in patients with HER2 positive metastatic or unresectable gastric or GEJ adenocarcinoma with disease progression on or after a trastuzumab-containing regimen.
  • The primary endpoint of the trial is overall survival. 
  • Secondary endpoints include investigator-assessed progression-free survival, objective response rate, duration of response, disease control rate, safety, pharmacokinetics, and immunogenicity.
  • The study will enroll approximately 490 patients.
  • Price Action: AZN shares are down 1.15% at $59.08 during the market session on the last check Thursday.
 

Related Articles (DSKYF + DSNKY)

View Comments and Join the Discussion!

Posted-In: Briefs stomach cancerBiotech News Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com